The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts
The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts
分析師總結：4位專家眼中的Lyell免疫藥物公司
An in-depth analysis of recent analyst...In the preceding three months, 4 analysts have released ratings for Lyell Immunopharma (NASDAQ:LYEL), presenting a wide array of perspectives from bullish to bearish.
在過去的三個月中，有4位分析師對Lyell Immunopharma（納斯達克股票代碼：LYEL）發佈了評級，展示了從看好到看淡的各種觀點。
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
下表總結了他們最近的評級，展示了過去30天內不斷變化的情緒，並將其與前幾個月進行了比較。
The 12-month price targets, analyzed by analysts, offer insights with an average target of $1.0, a high estimate of $1.00, and a low estimate of $1.00. Experiencing a 55.56% decline, the current average is now lower than the previous average price target of $2.25.
由分析師分析得出的12個月價格目標提供見解，平均目標價爲$1.0，最高估價爲$1.00，最低估價爲$1.00。經歷了55.56%的下跌，當前平均價低於先前的平均目標價$2.25。
Diving into Analyst Ratings: An In-Depth Exploration
深入探討分析師評級：分析師評級的深度探討
An in-depth analysis of recent analyst...
深入分析最近分...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間